Home InVivo Therapeutics Holdings

InVivo Therapeutics Holdings

INSPIRE 2.0 Study for the Treatment of Acute Spinal Cord Injury Enrollment Update

Richard Toselli, M.D., President and Chief Executive Officer of InVivo, said, “We made a dedicated effort to efficiently activate strategic clinical sites during the first half of the year and are pleased with the resulting pace of enrollment to date, with our team maintaining focus on enrollment efforts and engagement at the site level. In addition, we appreciate the investigators’ support of this trial, which we believe has the potential to address a long unmet medical need for spinal cord injury patients.”

InVivo Therapeutics Receives FDA Approval for Pivotal, Randomized, Controlled Trial of the Neuro-Spinal Scaffold™ in Patients with Acute Spinal Cord Injury

3/8/18: The Study is Designed to Enhance Clinical Evidence from INSPIRE Study and Support Potential Humanitarian Device Exemption (HDE) Submission

InVivo Therapeutics Appoints Richard Toselli, M.D. Chief Medical Officer

Richard Toselli, M.D., has been appointed Chief Medical Officer at InVivo Therapeutics.  His appointment becomes effective July 5, 2017. Dr. Toselli, a fellowship-trained spinal neurosurgeon, will assume all responsibilities related to the company’s clinical and regulatory strategy. Prior...

InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Thomas Jefferson University Hospital

InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS...

Update to the Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”)

Study to Include Reeve Foundation North American Clinical Trials Network (NACTN) Registry InVivo Therapeutics Holdings Corp. (NVIV) today announced that data from the Christopher & Dana Reeve Foundation NACTN Registry will be included in the Contemporary Thoracic SCI Registry...

InVivo Therapeutics Announces Presentation at Combined Canadian Spinal Cord and Ontario Spinal Cord Injury Research Network Meeting

InVivo Therapeutics Holdings Corp. (NVIV) today announced that Kristin Neff, Vice President, Clinical Operations, will present at the Combined Canadian Spinal Cord and Ontario Spinal Cord Injury Research Network Meeting on Saturday, May 13, 2017 at 2:40 PM...

InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Oregon Health and Science University

Company Notes:  Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing...

InVivo Therapeutics Announces Seventh Patient Conversion in The INSPIRE Study of the Neuro-Spinal Scaffold™

Two additional patients are early in follow-up and have not yet had their one-month visit. The AIS conversion rate observed in the INSPIRE study to date is considerably higher than published rates observed in a range of SCI natural history databases that are all below 25%.